Idera dumps its lead can­cer drug pro­gram; Pfiz­er won’t split up af­ter all

Once you work through an ex­pla­na­tion of all the rea­sons Idera Phar­ma­ceu­ti­cals $IDRA has found to be op­ti­mistic about its on­go­ing Phase I/II study of its TLR-9 drug IMO-2125, you’ll find that it has al­so punt­ed its lead drug. The Cam­bridge, MA-based biotech says that it is sus­pend­ing de­vel­op­ment of IMO-8400 for B-cell lym­phomas and will start ex­plor­ing “strate­gic op­tions.” The com­pa­ny says the lev­el of clin­i­cal ac­tiv­i­ty doesn’t war­rant de­vel­op­ment as a monother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER